TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. 28 0/7-36 6/7 weeks gestational age (GA) at birth;~2. family identifies the child as black or African American;~3. \< 28 days of supplemental oxygen (subsequent oxygen therapy for \< 72 hrs for a brief subsequent illness or surgery will be allowed);~4. admitted to a participating site NICU, special care nursery, transitional care nursery, or well-baby nursery as a neonate; and~5. \< 40 weeks corrected GA at enrollment.~Exclusion criteria:~1. BPD (\> 28 days of supplemental oxygen);~2. pre-existing diagnosis of moderate to severe osteopenia of prematurity and/or alkaline phosphatase \> 700;~3. history of fracture;~4. gastrointestinal surgery, including for NEC;~5. known gastrointestinal malabsorption;~6. major congenital anomaly;~7. congenital pulmonary or airway disorder (e.g., cystic fibrosis, tracheomalacia, swallowing disorder, bronchopulmonary sequestration);~8. documented wheezing or stridor prior to enrollment;~9. previous vit. D supplementation with \> 400 IU/day;~10. family plans to move more than 60 miles from CWRU or other pre-defined radius at other sites;~11. baseline hypo- or hypercalcemia, hypo- or hyperphosphatemia; and~12. baseline 25(OH) D level \< 10 ng/ml.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Year
- Healthy Volunteers: f

Study Arms:
- Sustained (Type: ACTIVE_COMPARATOR): Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
- Diet-Limited (Type: PLACEBO_COMPARATOR): Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lurasidone and Cognition in Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All patients must be taking either lithium or valproate or one of the atypical antipsychotics for mood stabilization.~2. Patients who show cognitive impairments (-0.25 standard deviations (SD) or below) on either the Trail Making Test- trial B (TMT-B) or California Verbal Learning Test (CVLT) trials 1 to 5, or CVLT long delay free recall, at baseline visit.~3. Males or females aged 19 to 65 years inclusive.~4. Diagnostic and Statistical Manual IV edition (DSM-IV TR) diagnosis of Bipolar Type I Disorder, with or without a history of psychosis.~5. Clinically stable with a Montgomery Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) score less than or equal to 8.~6. A sufficient level of English using a language screening questionnaire.~7. Capability of understanding, consenting to, and complying with the requirements of the study.~Exclusion Criteria:~1. A history of unstable or inadequately treated medical illnesses, including moderate to severe brain injury, or neurological illnesses impacting cognitive function.~2. Treatment with Electroconvulsive Therapy (ECT) within eight weeks prior to enrolment; or treatment with an experimental drug within 30 days prior to enrolment.~3. Axis I diagnosis of substance abuse or dependence within the past month.~4. Significant risk of harm to self or others, in the opinion of the investigator.~5. Pregnancy or lactation in female subjects.~6. Liver function tests (AST and ALT) three times the upper limit of normal. -

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lurasidone (Type: EXPERIMENTAL): Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
- Treatment as usual (Type: NO_INTERVENTION): Patients randomized to this arm will continue their usual treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Anorexia Nervosa on Bone Mass in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females Only with Anorexia Nervosa and Amenorrhea 12-18 years~* Normal-weight girls 12-18 years with no past or present history of an eating disorder~Exclusion Criteria:~* Diseases affecting bone metabolism (including untreated thyroid disease, premature ovarian failure, diabetes, cancer, pituitary, renal disease or bone fracture within the past six months)~* Use of prescription medications affecting bone metabolism within three months~* Suicidality~* Psychosis~* Substance abuse~* Hematocrit \<30 %~* Potassium \<3.0 mmol/L~* Glucose \<50 mg/dl.

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Physiologic estrogen replacement (Type: EXPERIMENTAL): Mature girls with anorexia nervosa (AN) (bone age 15 or greater): Transdermal estradiol (100 mcg) with cyclic progesterone (days 1-10 of each month).~Immature girls with AN (bone age less than 15 years): Ethinyl estradiol (3.75 mcg daily for the first 6 months, 7.5 mcg daily for the next 6 months, and 11.25 mcg daily for the final 6 months of the study
- Placebo (Type: PLACEBO_COMPARATOR): Placebo patches or pills

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Curatively resected HER2+ gastric or gastroesophageal junction adenocarcinoma; HER2+ status as defined by immunohistochemistry-2 positive or 3 positive with corroborative Fluorescence In Situ Hybridization+ result~* Participants with stages between Stage IB (T1N1M0) and Stage IIIC~* ECOG performance status score equal to or less than (\<=) 2 during screening~* Left ventricular ejection fraction equal to or higher than (\>=) 55% with acceptable levels of liver and renal functions~* No known contraindication to capecitabine, oxaliplatin, and trastuzumab~* No contraindication for radiotherapy or has not received any previous radiotherapy to the gastric region for any reason~Exclusion Criteria:~* Participants with a malign condition in the last 5 years except squamous cell carcinoma of the skin~* Previous neoadjuvant chemotherapy and/or radiotherapy~* Any disruption in the physical integrity of the upper gastrointestinal tract (except surgical intervention for gastric or gastroesophageal junction carcinoma)~* Known (previously diagnosed and ongoing) malabsorption syndrome~* Active gastrointestinal bleeding~* Participants with Stage IV gastric or gastroesophageal junction adenocarcinoma~* Clinically significant cardiac or cardiovascular disease~* Uncontrolled hypertension~* Participants who have received any investigational anti-cancer treatment or are being treated in a concomitant investigational drug study~* Abnormal laboratory values at screening for serum total bilirubin, alanine aminotransferase or aspartate amino transferase, alkaline phosphatase, absolute neutrophil count, platelet count, and/or hemoglobin~* Known or suspected hypersensitivity against trastuzumab or proteins of rodents~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Combination Therapy (Type: EXPERIMENTAL): Participants will receive combination therapy comprising of trastuzumab, oxaliplatin, capecitabine, and radiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AryoTrust® (Trastuzumab) Safety Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with HER2-positive breast cancer undergoing adjuvant chemotherapy regimens~Exclusion Criteria:~* Patients who had received Trastuzumab as part of their therapy or were not candidates for treatment continuation after adjuvant chemotherapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AryoGen Pharmed Trastuzumab (Type: None): AryoTrust is given at dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B504

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age and older~* Patients scheduled to undergo ileostomy reversal~* Ability to provide informed consent, adhere to study visit schedule, and complete all assessments.~Exclusion Criteria:~* Patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioid, or propofol.~* Patients who abuse alcohol or other drug substance.~* Patients with severe hepatic impairment.~* Patients currently pregnant or who may become pregnant during the course of the study or who are unwilling to use acceptable means of contraception for at lest one month before and one month after dosing.~* Patients with any psychiatric, psychological, or other condition that the Investigator feels may make the patient an inappropriate candidate for this clinical study.~* Patients who have participated in an EXPAREL study within the last 30 days.~* Patients who have received an investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the patient's participation in this study.~In addition, the patient will be ineligible if he/she meets the following criteria during surgery:~* Patients who have any concurrent surgical procedure.~* Patients who receive intraoperative administration of opioids (other than fentanyl or analogs) or any other analgesic, local anesthetics, or anti-inflammatory agents.~* Patients who receive Entereg(R).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): IV morphine sulfate (or Sponsor-approved equivalent), Standard of Care (SOC)
- Group 2 (Type: EXPERIMENTAL): EXPAREL (bupivacaine liposome injectable suspension)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Daily Activity After Corticosteroids Injection Among Knee Osteoarthritis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 50 years old or more~* Medial knee osteoarthritis (Kellgren \& Lawrence Grade I to III)~Exclusion Criteria:~* Intra-articular injection during the last six months~* Isolated femoro-patellar arthritis~* Rheumatoid arthritis~* Knee instability~* Spinal stenosis~* Lower limb fracture over the last year~* Lower limb surgery in the last three months

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Injection (Type: EXPERIMENTAL): Corticosteroids injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 2 years postmenopausal~* Osteoporotic subjects without vertebral fracture who meet BMD criteria, or Osteoporotic subjects with vertebral fracture~Exclusion Criteria:~* Diseases that may affect bone metabolism~* Vasomotor symptoms requiring treatment~* Known history or suspected cancer of the breast~* Active or past history of venous thromboembolic events

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has Type 2 diabetes~* Currently taking metformin \>1500 mg/day for at least 10 weeks~* Male or female~Exclusion Criteria:~* Patient has peripheral edema~* History of type 1 diabetes~* Patient required insulin within prior 8 weeks~* Have participated or are currently participating in another study with an investigational compound or device within 12 weeks of starting this study~* Participating in a weight loss program

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): sitagliptin 100 mg
- Rosiglitazone (Type: ACTIVE_COMPARATOR): rosiglitazone 8 mg
- Placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Coronary heart disease~* Type 2 diabetes~Exclusion Criteria:~* Severe organ dysfunction, psychopathy, infection, neutropenia~* Congenital heart disease, rheumatic heart disease, severe arrhythmia, myocardiopathy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- metformin (Type: ACTIVE_COMPARATOR): None
- glipizide (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults at least 18 years of age~* Patients with signs and symptoms consistent with acute herpes zoster disease, namely, a dermatomal vesicular rash which may be preceded by pain and parasthesias in the days before vesicular eruption~* Herpes Zoster associated rash present for ≤ 72 hours~* Patients who are deemed to be immunocompetent based on history and physical exam~Exclusion Criteria:~* Females who are pregnant or nursing~* History or clinical manifestations of significant metabolic, hematological, pulmonary, ischemic, or unstable heart disease, gastrointestinal, neurological, psychiatric, renal, urological, endocrine, opthalmologic, or immune mediated disease including HIV or HBsAg positivity~* Chronic genital herpes~* Patients who received cytotoxic or immunosuppressive drug therapy within 3 months prior to study participation~* Previous vaccinations against Herpes Zoster~* Patients with \> 50% of vesicles crusted at screen~* Patients who received topical or systemic antiviral medications or immunomodulatory agents for herpes zoster viral infections or capsaicin within 4 weeks of study participation~* Patients with a history of congenital, acquired, or corticosteroid induced immunodeficiency, including malignancy, significantly impaired renal function (creatinine clearance \< 50 cc/min), and impaired hepatic function (ALT or AST levels \> 3 times the upper limit of normal)~* QTc \> 500msec~* Patients with a history of intolerance or hypersensitivity to acyclovir, penciclovir, valacyclovir, or famciclovir~* Patients with gastrointestinal dysfunction that might interfere with drug absorption~* Patients, considered by the investigator, for any reason, to be an unsuitable candidate for receiving the study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EPB-348 1000 mg (Type: EXPERIMENTAL): EPB-348 1000 mg dosed once daily for seven days
- EPB-348 2000 mg (Type: EXPERIMENTAL): EPB-348 2000 mg dosed once daily for seven days
- EPB-348 3000 mg (Type: EXPERIMENTAL): EPB-348 3000 mg dosed once daily for seven days
- Valacyclovir (Type: ACTIVE_COMPARATOR): Valacyclovir 1000 mg dosed three times daily for seven days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* have type 2 diabetes as defined by World Health Organization (WHO) criteria~* are taking oral anti-hyperglycemic medications (OAMs) and are judged as OAM failure by the investigator~* most recent HbA1c value ≥7.5% within 12 weeks of study entry~* in the opinion of the investigator, require to initiate premix analog or basal insulin analog treatment~* willing to start with insulin treatment~Exclusion Criteria:~* have a diagnosis of type 1 diabetes~* have received any type of insulin within 24 months of study entry (except for intermittent use of insulin of less than 1 month each time)~* have serious preexisting medical or other conditions that, in the judgment of the investigator, would preclude participation in this study~* are pregnant or breastfeeding, or intend to become pregnant during the course of the study~* are currently enrolled or have participated, within the last 30 days in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Insulin Analog Mid Mixture (Type: EXPERIMENTAL): Insulin analog mid mixture given subcutaneously (SC).
- Basal Insulin Analog (Type: EXPERIMENTAL): Basal insulin analog given SC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Sirolimus for In-Stent Restenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with angina pectoris or exercise-induced ischemia in the presence of angiographically significant in-stent-restenosis in native coronary arteries.~Exclusion Criteria:~* Patients with acute coronary syndromes or with severe infectious diseases the presence of severe kidney failure (serum creatinine \> 2.2 mg/dl) contraindications to sirolimus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): cumulative loading dose of 8 mg of sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
- 2 (Type: ACTIVE_COMPARATOR): cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
- 3 (Type: PLACEBO_COMPARATOR): oral placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete